

Ian D Pavord

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4449014/publications.pdf>

Version: 2024-02-01

224
papers

31,364
citations

10986

71
h-index

4432

172
g-index

231
all docs

231
docs citations

231
times ranked

17138
citing authors

#	ARTICLE	IF	CITATIONS
1	Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2012, 380, 651-659.	13.7	1,849
2	Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. <i>New England Journal of Medicine</i> , 2014, 371, 1198-1207.	27.0	1,807
3	Cluster Analysis and Clinical Asthma Phenotypes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 218-224.	5.6	1,727
4	Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma. <i>New England Journal of Medicine</i> , 2009, 360, 973-984.	27.0	1,672
5	Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. <i>Lancet, The</i> , 2002, 360, 1715-1721.	13.7	1,598
6	An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 59-99.	5.6	1,591
7	Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma. <i>New England Journal of Medicine</i> , 2014, 371, 1189-1197.	27.0	1,331
8	Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. <i>New England Journal of Medicine</i> , 2018, 378, 2486-2496.	27.0	1,253
9	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. <i>European Respiratory Journal</i> , 2019, 53, 1900164.	6.7	1,223
10	Mast-Cell Infiltration of Airway Smooth Muscle in Asthma. <i>New England Journal of Medicine</i> , 2002, 346, 1699-1705.	27.0	1,147
11	Acute Exacerbations of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 662-671.	5.6	847
12	Treatable traits: toward precision medicine of chronic airway diseases. <i>European Respiratory Journal</i> , 2016, 47, 410-419.	6.7	746
13	After asthma: redefining airways diseases. <i>Lancet, The</i> , 2018, 391, 350-400.	13.7	744
14	Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. <i>Lancet Respiratory Medicine, the</i> , 2015, 3, 435-442.	10.7	583
15	Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. <i>Lancet, The</i> , 2000, 356, 1480-1485.	13.7	514
16	Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 48-55.	5.6	499
17	Non-eosinophilic corticosteroid unresponsive asthma. <i>Lancet, The</i> , 1999, 353, 2213-2214.	13.7	473
18	Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. <i>Lancet Respiratory Medicine, the</i> , 2015, 3, 849-858.	10.7	443

#	ARTICLE	IF	CITATIONS
19	Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. <i>Lancet Respiratory Medicine</i> , 2016, 4, 549-556.	10.7	433
20	Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1613-1629.	27.0	397
21	Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. <i>Thorax</i> , 2007, 62, 1043-1049.	5.6	396
22	Safety and Efficacy of Bronchial Thermoplasty in Symptomatic, Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 1185-1191.	5.6	387
23	Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank. <i>Lancet Respiratory Medicine</i> , 2015, 3, 769-781.	10.7	346
24	Controlled Trial of Budesonide Formoterol as Needed for Mild Asthma. <i>New England Journal of Medicine</i> , 2019, 380, 2020-2030.	27.0	308
25	Blood eosinophils and inhaled corticosteroid/long-acting β_2 -agonist efficacy in COPD. <i>Thorax</i> , 2016, 71, 118-125.	5.6	288
26	Fevipiprant, a prostaglandin D ₂ receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2016, 4, 699-707.	10.7	220
27	A worldwide survey of chronic cough: a manifestation of enhanced somatosensory response. <i>European Respiratory Journal</i> , 2014, 44, 1149-1155.	6.7	202
28	Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. <i>New England Journal of Medicine</i> , 2021, 385, 1656-1668.	27.0	183
29	Biomarkers for severe eosinophilic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1509-1518.	2.9	180
30	Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report. <i>European Respiratory Journal</i> , 2019, 53, 1802058.	6.7	177
31	Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 909-923.	10.7	177
32	A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. <i>Cell</i> , 2022, 185, 916-938.e58.	28.9	164
33	Eosinophils in COPD: just another biomarker?. <i>Lancet Respiratory Medicine</i> , 2017, 5, 747-759.	10.7	160
34	Current evidence and future research needs for FeNO measurement in respiratory diseases. <i>Respiratory Medicine</i> , 2014, 108, 830-841.	2.9	157
35	Precision medicine in airway diseases: moving to clinical practice. <i>European Respiratory Journal</i> , 2017, 50, 1701655.	6.7	151
36	Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 921-923.	2.9	150

#	ARTICLE	IF	CITATIONS
37	Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. <i>Lancet Respiratory Medicine</i> , 2016, 4, 731-741.	10.7	147
38	Management of chronic cough. <i>Lancet</i> , 2008, 371, 1375-1384.	13.7	144
39	An expert consensus framework for asthma remission as a treatment goal. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 757-765.	2.9	144
40	Severe eosinophilic asthma: a roadmap to consensus. <i>European Respiratory Journal</i> , 2017, 49, 1700634.	6.7	143
41	Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. <i>European Respiratory Journal</i> , 2014, 44, 789-791.	6.7	141
42	Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 69-84.	10.7	135
43	Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. <i>Lancet</i> , 2022, 399, 909-923.	13.7	131
44	Cysteinyl leukotriene E 4 activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D 2 and epithelial cytokines. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1090-1100.e11.	2.9	130
45	Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. <i>Advances in Therapy</i> , 2018, 35, 737-748.	2.9	129
46	Blood Eosinophils and Outcomes in Severe Hospitalized Exacerbations of COPD. <i>Chest</i> , 2016, 150, 320-328.	0.8	125
47	Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 2027-2036.e12.	2.9	124
48	Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 516-526.	3.8	123
49	Quadrupling Inhaled Glucocorticoid Dose to Abort Asthma Exacerbations. <i>New England Journal of Medicine</i> , 2018, 378, 902-910.	27.0	119
50	Remotely Monitored Therapy and Nitric Oxide Suppression Identifies Nonadherence in Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 454-464.	5.6	115
51	Monitoring asthma in children. <i>European Respiratory Journal</i> , 2015, 45, 906-925.	6.7	114
52	Biological clustering supports both the Dutch and British hypotheses of asthma and chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 63-72.e10.	2.9	111
53	Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. <i>Lancet Respiratory Medicine</i> , 2022, 10, 11-25.	10.7	109
54	Monitoring asthma in childhood: lung function, bronchial responsiveness and inflammation. <i>European Respiratory Review</i> , 2015, 24, 204-215.	7.1	103

#	ARTICLE	IF	CITATIONS
55	Physiotherapy breathing retraining for asthma: a randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2018, 6, 19-28.	10.7	97
56	Asthma progression and mortality: the role of inhaled corticosteroids. <i>European Respiratory Journal</i> , 2019, 54, 1900491.	6.7	96
57	Associations between blood eosinophils and decline in lung function among adults with and without asthma. <i>European Respiratory Journal</i> , 2018, 51, 1702536.	6.7	93
58	Safety of bronchial thermoplasty in patients with severe refractory asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2013, 111, 402-407.	1.0	91
59	Composite type-2 biomarker strategy versus a symptom-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 57-68.	10.7	88
60	Prognostic and Predictive Value of Blood Eosinophil Count, Fractional Exhaled Nitric Oxide, and Their Combination in Severe Asthma: A Post Hoc Analysis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 1308-1312.	5.6	87
61	Inhaled Corticosteroid Therapy in Adult Asthma. Time for a New Therapeutic Dose Terminology. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1471-1477.	5.6	87
62	Blood eosinophil levels as a biomarker in COPD. <i>Respiratory Medicine</i> , 2018, 138, 21-31.	2.9	86
63	A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis. <i>European Respiratory Journal</i> , 2015, 46, 1021-1032.	6.7	85
64	Multidimensional assessment of severe asthma: A systematic review and meta-analysis. <i>Respirology</i> , 2017, 22, 1262-1275.	2.3	82
65	Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. <i>European Respiratory Journal</i> , 2020, 55, 2000351.	6.7	81
66	Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 671-680.	10.7	81
67	Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK). <i>Thorax</i> , 2016, 71, 187-189.	5.6	78
68	Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1167-1175.e2.	2.9	78
69	A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. <i>European Respiratory Journal</i> , 2016, 48, 320-330.	6.7	77
70	Eosinophil protein in airway macrophages: A novel biomarker of eosinophilic inflammation in patients with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 61-69.e3.	2.9	76
71	Effectiveness of voriconazole in the treatment of <i>Aspergillus fumigatus</i> -associated asthma (EVITA3) Tj ETQq1 1 0,784314 rgBT /Over	2.9	74
72	Association Between Pathogens Detected Using Quantitative Polymerase Chain Reaction With Airway Inflammation in COPD at Stable State and Exacerbations. <i>Chest</i> , 2015, 147, 46-55.	0.8	74

#	ARTICLE	IF	CITATIONS
73	Inflammometry to assess airway diseases. <i>Lancet, The</i> , 2008, 372, 1017-1019.	13.7	72
74	Fractional exhaled nitric oxide for the management of asthma in adults: a systematic review. <i>European Respiratory Journal</i> , 2016, 47, 751-768.	6.7	72
75	Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide. <i>Thorax</i> , 2022, 77, 199-202.	5.6	70
76	Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1165-1173.	10.7	70
77	Eosinophil Knockout Humans: Uncovering the Role of Eosinophils Through Eosinophil-Directed Biological Therapies. <i>Annual Review of Immunology</i> , 2021, 39, 719-757.	21.8	69
78	Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1130-1140.	10.7	65
79	Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, 1083-1089.e7.	2.9	64
80	The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β_2 -agonists in the United Kingdom: a cross-sectional analysis. <i>Npj Primary Care Respiratory Medicine</i> , 2017, 27, 17.	2.6	64
81	Blood eosinophil count and exacerbation risk in patients with COPD. <i>European Respiratory Journal</i> , 2017, 50, 1700761.	6.7	64
82	Asthma remission: what is it and how can it be achieved?. <i>European Respiratory Journal</i> , 2022, 60, 2102583.	6.7	61
83	DP β_2 antagonism reduces airway smooth muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	57
84	Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 17-24.	5.6	57
85	Measurement of exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and NObreath. <i>Health Technology Assessment</i> , 2015, 19, 1-330.	2.8	54
86	Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma. <i>Lancet Respiratory Medicine</i> , 2016, 4, 585-592.	10.7	53
87	The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1174-1184.	10.7	49
88	Eosinophilic Phenotypes of Airway Disease. <i>Annals of the American Thoracic Society</i> , 2013, 10, S143-S149.	3.2	46
89	Synergistic activation of pro-inflammatory type-2 CD8+ T lymphocytes by lipid mediators in severe eosinophilic asthma. <i>Mucosal Immunology</i> , 2018, 11, 1408-1419.	6.0	46
90	Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations. <i>Clinical and Translational Allergy</i> , 2019, 9, 41.	3.2	46

#	ARTICLE	IF	CITATIONS
91	Predictors of objective cough frequency in pulmonary sarcoidosis. <i>European Respiratory Journal</i> , 2016, 47, 1461-1471.	6.7	43
92	Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort. <i>European Respiratory Journal</i> , 2021, 58, 2003927.	6.7	43
93	Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma. <i>European Respiratory Journal</i> , 2021, 58, 2100413.	6.7	43
94	A cross-sectional study of patterns of airway dysfunction, symptoms and morbidity in primary care asthma. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2012, 21, 283-287.	2.3	40
95	Blood eosinophil count: a biomarker of an important treatable trait in patients with airway disease. <i>European Respiratory Journal</i> , 2016, 47, 1299-1303.	6.7	40
96	Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough. <i>ERJ Open Research</i> , 2020, 6, 00284-2020.	2.6	40
97	Fractional Exhaled Nitric Oxide Nonsuppression Identifies Corticosteroid-Resistant Type 2 Signaling in Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 731-734.	5.6	40
98	Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma. <i>Therapeutic Advances in Respiratory Disease</i> , 2015, 9, 135-145.	2.6	39
99	Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients. <i>PLoS Pathogens</i> , 2021, 17, e1009804.	4.7	39
100	Primary Human Airway Epithelial Cell-Dependent Inhibition of Human Lung Mast Cell Degranulation. <i>PLoS ONE</i> , 2012, 7, e43545.	2.5	37
101	Exhaled nitric oxide and blood eosinophilia: Independent markers of preventable risk. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 828-829.	2.9	34
102	Sputum microbiomic clustering in asthma and chronic obstructive pulmonary disease reveals a <i>Haemophilus</i> predominant subgroup. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 808-817.	5.7	33
103	The burden of exacerbations in mild asthma: a systematic review. <i>ERJ Open Research</i> , 2020, 6, 00359-2019.	2.6	33
104	Severe T2-high asthma in the biologics era: European experts' opinion. <i>European Respiratory Review</i> , 2019, 28, 190054.	7.1	32
105	Optimal Asthma Control: Time for a New Target. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1480-1487.	5.6	32
106	Risk Predictors and Symptom Features of Long COVID Within a Broad Primary Care Patient Population Including Both Tested and Untested Patients. <i>Journal of Pragmatic and Observational Research</i> , 2021, Volume 12, 93-104.	1.5	32
107	Unmet Needs in Severe Asthma Subtyping and Precision Medicine Trials. Bridging Clinical and Patient Perspectives. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 823-829.	5.6	31
108	A new approach to the classification and management of airways diseases: identification of treatable traits. <i>Clinical Science</i> , 2017, 131, 1027-1043.	4.3	30

#	ARTICLE	IF	CITATIONS
109	Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO. International Journal of COPD, 2021, Volume 16, 1755-1770.	2.3	30
110	The asthmas in 2015 and beyond: a Lancet Commission. Lancet, The, 2015, 385, 1273-1275.	13.7	29
111	Prospective observational study in patients with obstructive lung disease: NOVELTY design. ERJ Open Research, 2019, 5, 00036-2018.	2.6	29
112	Moving towards a Treatable Traits model of care for the management of obstructive airways diseases. Respiratory Medicine, 2021, 187, 106572.	2.9	29
113	Biologics and chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2018, 141, 1983-1991.	2.9	28
114	Association between blood eosinophil count and risk of readmission for patients with asthma: Historical cohort study. PLoS ONE, 2018, 13, e0201143.	2.5	28
115	A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial. Trials, 2018, 19, 5.	1.6	26
116	Oral corticosteroid-dependent asthma. Current Opinion in Pulmonary Medicine, 2019, 25, 51-58.	2.6	26
117	ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma. European Respiratory Journal, 2020, 55, 1901407.	6.7	26
118	Using fractional exhaled nitric oxide to guide step-down treatment decisions in patients with asthma: a systematic review and individual patient data meta-analysis. European Respiratory Journal, 2020, 55, 1902150.	6.7	26
119	The Use of Exhaled Nitric Oxide in the Management of Asthma. Journal of Asthma, 2008, 45, 523-531.	1.7	25
120	Anti-IL-4/IL-13 for the treatment of asthma: the story so far. Expert Opinion on Biological Therapy, 2020, 20, 283-294.	3.1	25
121	A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials, 2020, 21, 718.	1.6	25
122	Dupilumab is effective in type 2 ^{high} asthma patients receiving high ^{high} dose inhaled corticosteroids at baseline. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 269-280.	5.7	25
123	From DREAM to REALTI ^{EA} and beyond: Mepolizumab for the treatment of eosinophil ^{driven} diseases. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 778-797.	5.7	25
124	A retrospective cohort study in severe asthma describing commonly measured biomarkers: Eosinophil count and IgE levels. Respiratory Medicine, 2018, 134, 117-123.	2.9	24
125	<p>Asthma impacts on workplace productivity in employed patients who are symptomatic despite background therapy: a multinational survey</p>. Journal of Asthma and Allergy, 2019, Volume 12, 183-194.	3.4	23
126	Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype Oxford Asthma Attack Risk Scale (ORACLE). ERJ Open Research, 2022, 8, 00570-2021.	2.6	23

#	ARTICLE	IF	CITATIONS
127	Cough and asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , 2004, 17, 399-402.	2.6	22
128	Four-Hour Cough Frequency Monitoring in Chronic Cough. <i>Chest</i> , 2012, 142, 1237-1243.	0.8	22
129	Measuring lung function in airways diseases: current and emerging techniques. <i>Thorax</i> , 2019, 74, 797-805.	5.6	21
130	Usability of mepolizumab single-use prefilled autoinjector for patient self-administration. <i>Journal of Asthma</i> , 2020, 57, 987-998.	1.7	21
131	Controversies in Allergy: Choosing a Biologic for Patients with Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 410-419.	3.8	21
132	First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis. <i>Npj Primary Care Respiratory Medicine</i> , 2016, 26, 16061.	2.6	20
133	Interleukin-5 Inhibitors for Severe Asthma: Rationale and Future Outlook. <i>BioDrugs</i> , 2017, 31, 93-103.	4.6	20
134	Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 874-882.e4.	3.8	19
135	Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1121-1132.e7.	3.8	19
136	A randomised controlled trial of small particle inhaled steroids in refractory eosinophilic asthma (SPIRA). <i>Thorax</i> , 2015, 70, 559-565.	5.6	18
137	Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma. <i>European Respiratory Journal</i> , 2016, 47, 981-984.	6.7	18
138	The Objective Assessment of Cough Frequency in Bronchiectasis. <i>Lung</i> , 2017, 195, 575-585.	3.3	18
139	Balancing the needs of the many and the few: where next for adult asthma guidelines?. <i>Lancet Respiratory Medicine</i> , 2021, 9, 786-794.	10.7	18
140	Workup of Severe Asthma. <i>Chest</i> , 2021, 160, 2019-2029.	0.8	18
141	Substratification of type 2 high airway disease for therapeutic decision-making: A bomb (blood) Tj ET Og1 1 0.784314 rgB	2.3	18
142	Complex airway disease: an approach to assessment and management. <i>Lancet Respiratory Medicine</i> , 2013, 1, 84-90.	10.7	16
143	Exacerbations of severe asthma in patients treated with mepolizumab. <i>European Respiratory Journal</i> , 2018, 52, 1801127.	6.7	16
144	Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2621-2624.	5.7	16

#	ARTICLE	IF	CITATIONS
145	Morbidity associated with oral corticosteroids in patients with severe asthma. <i>Thorax</i> , 2016, 71, 302-304.	5.6	15
146	<p>Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function</p>. <i>Journal of Asthma and Allergy</i> , 2020, Volume 13, 701-711.	3.4	14
147	Exacerbation Profile and Risk Factors in a Type-2âledquoLow Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 545-553.	5.6	14
148	Two Lovely Black Eyes; Oh, what a surprise!. <i>Thorax</i> , 2015, 70, 609-610.	5.6	13
149	Pointâleofâlecare biomarkers in asthma management: Time to move forward. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 995-997.	5.7	13
150	Asthma in pregnancy: An update. <i>Obstetric Medicine</i> , 2021, 14, 135-144.	1.1	13
151	Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma. <i>Respiratory Medicine</i> , 2022, 191, 105991.	2.9	13
152	A randomised controlled study of the effectiveness of breathing retraining exercises taught by a physiotherapist either by instructional DVD or in face-to-face sessions in the management of asthma in adults. <i>Health Technology Assessment</i> , 2017, 21, 1-162.	2.8	13
153	Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough. <i>Annals of Allergy, Asthma and Immunology</i> , 2023, 130, 60-66.	1.0	13
154	Asthma diagnosis: addressing the challenges. <i>Lancet Respiratory Medicine</i> , the, 2015, 3, 339-341.	10.7	12
155	Defining severe obstructive lung disease in the biologic era: an endotype-based approach. <i>European Respiratory Journal</i> , 2019, 54, 1900108.	6.7	12
156	Blood eosinophils to guide inhaled maintenance therapy in a primary care COPD population. <i>ERJ Open Research</i> , 2022, 8, 00606-2021.	2.6	12
157	Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma. <i>Respiratory Research</i> , 2007, 8, 67.	3.6	11
158	Fevipirant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2329-2333.	2.9	11
159	Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. <i>Annals of the American Thoracic Society</i> , 2019, 16, 29-39.	3.2	11
160	Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarkerâlehigh and âlelow severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2974-2986.	5.7	11
161	âleWe canâleTM diagnose asthma until <insert arbitrary age>âleTM. <i>Archives of Disease in Childhood</i> , 2018, 103, 729-731.	1.9	10
162	Blood Eosinophilâle-directed Management of Airway Disease. The Past, Present, and Future. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 637-639.	5.6	10

#	ARTICLE	IF	CITATIONS
163	Budesonide–formoterol reliever therapy in intermittent <i>versus</i> mild persistent asthma. European Respiratory Journal, 2021, 57, 2003064.	6.7	10
164	Management Strategies to Reduce Exacerbations in non-T2 Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2588-2597.	3.8	10
165	Perspectives of mild asthma patients on maintenance versus as-needed preventer treatment regimens: a qualitative study. BMJ Open, 2022, 12, e048537.	1.9	10
166	Should we apply a treatable traits approach to asthma care?. Annals of Allergy, Asthma and Immunology, 2022, 128, 390-397.	1.0	10
167	Emerging Biologics in Severe Asthma. Immunology and Allergy Clinics of North America, 2016, 36, 609-623.	1.9	9
168	Theobromine for the treatment of persistent cough: a randomised, multicentre, double-blind, placebo-controlled clinical trial. Journal of Thoracic Disease, 2017, 9, 1864-1872.	1.4	8
169	&p'The acute wheezy adult with airways disease in the emergency department: a retrospective case-note review of exacerbations of COPD&p'. International Journal of COPD, 2019, Volume 14, 971-977.	2.3	8
170	The Roles of Type 2 Cytotoxic T Cells in Inflammation, Tissue Remodeling, and Prostaglandin (PG) D2 Production Are Attenuated by PGD2 Receptor 2 Antagonism. Journal of Immunology, 2021, 206, 2714-2724.	0.8	8
171	Challenging the paradigm: moving from umbrella labels to treatable traits in airway disease. Breathe, 2021, 17, 210053.	1.3	8
172	Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma. European Respiratory Journal, 2022, 59, 2100768.	6.7	8
173	Blood eosinophil counts as markers of response to inhaled corticosteroids in COPD? “ Authors' reply. Lancet Respiratory Medicine, the, 2015, 3, e27.	10.7	7
174	Dose-response relationship of ICS/fast-onset LABA as reliever therapy in asthma. BMC Pulmonary Medicine, 2019, 19, 264.	2.0	7
175	Blood eosinophil count predicts treatment failure and hospital readmission for COPD. ERJ Open Research, 2020, 6, 00188-2020.	2.6	7
176	Forthcoming UK asthma guidelines: an opportunity to improve asthma outcomes. Lancet, The, 2021, 398, 1856-1858.	13.7	7
177	Blood eosinophils, fractional exhaled nitric oxide and the risk of asthma attacks in randomised controlled trials: protocol for a systemic review and control arm patient-level meta-analysis for clinical prediction modelling. BMJ Open, 2022, 12, e058215.	1.9	7
178	Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3362-3376.	5.7	7
179	Treating asthma exacerbations in athletes: TUE or not TUE?. Lancet Respiratory Medicine, the, 2018, 6, 8-10.	10.7	6
180	Fluticasone furoate: <sc>CAPTAIN</sc> of fluticasones in type 2 inflammatory asthma. Respiriology, 2022, 27, 184-186.	2.3	6

#	ARTICLE	IF	CITATIONS
181	Improving Care in Eosinophil-Associated Diseases: A Charter. <i>Advances in Therapy</i> , 2022, 39, 2323-2341.	2.9	6
182	Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing. <i>Thorax</i> , 2022, 77, 933-938.	5.6	6
183	Biomarkers and inhaled corticosteroid responsiveness in asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 884-885.	2.9	5
184	What can we learn from blood granulocyte patterns in patients with asthma?. <i>European Respiratory Journal</i> , 2016, 48, 976-978.	6.7	5
185	Mepolizumab, quality of life, and severe eosinophilic asthma. <i>Lancet Respiratory Medicine</i> , 2017, 5, 362-363.	10.7	5
186	Azithromycin in uncontrolled asthma. <i>Lancet</i> , 2017, 390, 629-630.	13.7	5
187	Do we really need a new classification of airway diseases?. <i>Lancet Respiratory Medicine</i> , 2018, 6, 891-893.	10.7	5
188	Resistance to apoptosis underpins the corticosteroid insensitivity of group 2 innate lymphoid cells. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1722-1726.e10.	2.9	5
189	Targeted biologic therapy for asthma. <i>British Medical Bulletin</i> , 2020, 133, 16-35.	6.9	5
190	Identifying Bacterial Airways Infection in Stable Severe Asthma Using Oxford Nanopore Sequencing Technologies. <i>Microbiology Spectrum</i> , 2022, 10, e0227921.	3.0	5
191	FourFold Asthma Study (FAST): a study protocol for a randomised controlled trial evaluating the clinical cost-effectiveness of temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations. <i>Trials</i> , 2016, 17, 499.	1.6	4
192	After the asthmas: Star Wars and Star Trek. <i>European Respiratory Journal</i> , 2017, 50, 1701362.	6.7	4
193	Cytometric Gating Stringency Impacts Studies of Type 2 Innate Lymphoid Cells in Asthma. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2017, 57, 745-747.	2.9	4
194	COUNTERPOINT: Should an Attempt Be Made to Withdraw Inhaled Corticosteroids in All Patients With Stable GOLD 3 (30% \hat{A} % \hat{A} FEV1 \hat{A} < 50% Predicted) COPD? No. <i>Chest</i> , 2018, 153, 782-784.	0.8	4
195	Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations. <i>Respiratory Medicine</i> , 2019, 154, 27-33.	2.9	4
196	Response to mepolizumab treatment is sustained across 4-weekly dosing periods. <i>ERJ Open Research</i> , 2020, 6, 00068-2020.	2.6	4
197	Biomarkers of Type 2 Airway Inflammation in Airway Disease: And Then There Were Two. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2640-2642.	3.8	4
198	Temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations: FAST. <i>Health Technology Assessment</i> , 2018, 22, 1-82.	2.8	4

#	ARTICLE	IF	CITATIONS
199	Step 4: stick or twist? A review of asthma therapy. <i>BMJ Open Respiratory Research</i> , 2016, 3, e000143.	3.0	3
200	Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1430-1436.	3.8	3
201	Baseline FeNO as a Prognostic Biomarker for Subsequent Severe Asthma Exacerbations in Patients With Uncontrolled, Moderate-to-Severe Asthma Receiving Placebo in the LIBERTY ASTHMA QUEST Study. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, AB21.	2.9	3
202	Pre-existing asthma as a comorbidity does not modify cytokine responses and severity of COVID-19. <i>Allergy, Asthma and Clinical Immunology</i> , 2021, 17, 67.	2.0	3
203	Biological Therapies for Asthma. , 2022, , 411-434.		3
204	Lessons from LAVOLTA. <i>Lancet Respiratory Medicine</i> , 2016, 4, 764-765.	10.7	2
205	COPD exacerbation phenotypes: The next frontier. <i>Respirology</i> , 2020, 25, 230-231.	2.3	2
206	A golden age of asthma research. <i>European Respiratory Journal</i> , 2020, 56, 2003820.	6.7	2
207	Variability in airway inflammation, symptoms, lung function and reliever use in asthma: anti-inflammatory reliever hypothesis and STIFLE study design. <i>ERJ Open Research</i> , 2020, 6, 00333-2019.	2.6	2
208	A Proposed Revision of the Stepwise Treatment Algorithm in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 100-103.	5.6	2
209	Look back with (some) anger, and a lot of pleasure. <i>Thorax</i> , 2015, 70, 819-821.	5.6	1
210	Inhaled corticosteroid dose-response on blood eosinophils in asthma – Authors' reply. <i>Lancet Respiratory Medicine</i> , 2016, 4, e1-e2.	10.7	1
211	GLUCOLD, eosinophils and chronic obstructive pulmonary disease. <i>Respirology</i> , 2018, 23, 966-967.	2.3	1
212	Thorax: the prostate years. <i>Thorax</i> , 2014, 69, 3-4.	5.6	0
213	Year in review 2014. Paediatric and adult clinical studies. <i>Thorax</i> , 2015, 70, 368-372.	5.6	0
214	Comment on: ‘‘Cost Effectiveness of Tiotropium in Patients with Asthma Poorly Controlled on Inhaled Glucocorticosteroids and Long-Acting Î2-Agonists’’. <i>Applied Health Economics and Health Policy</i> , 2016, 14, 117-118.	2.1	0
215	Rebuttal From Dr Pavord. <i>Chest</i> , 2018, 153, 786-787.	0.8	0
216	Will precision medicine become an effective tool for airway disease?. <i>Personalized Medicine</i> , 2018, 15, 243-245.	1.5	0

#	ARTICLE	IF	CITATIONS
217	Reply to Boulet and Nair: Inhaled Corticosteroids and Adult Asthma. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1557-1558.	5.6	0
218	Response to the correspondence: "Non-optimal methodology questions indirect treatment comparison of dupilumab vs other biologics in severe asthma". Respiratory Medicine, 2022, 191, 106088.	2.9	0
219	Response to comment on: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma (Respir. Med. 2020). Respiratory Medicine, 2022, 191, 106106.	2.9	0
220	Using fractional exhaled nitric oxide to guide step-down treatment decisions in asthma: practical considerations. European Respiratory Journal, 2020, 56, 2002809.	6.7	0
221	Achieving the balance between evidence and simplicity. European Respiratory Journal, 2020, 55, 2000651.	6.7	0
222	Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: A meta-analysis. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3506-3509.e3.	3.8	0
223	The Use of Inhaled Corticosteroids to Prevent Acute Exacerbations of COPD: A Pro/Con Debate. Turkish Thoracic Journal, 2019, 20, 198-202.	0.6	0
224	Reply to: Challenging the paradigm. Breathe, 2022, 18, 210174.	1.3	0